Eli Lilly’s (LLY) Loxo and Foghorm (FHTX) Collaborate for Novel Oncology Targets using Foghorn’s Gene Traffic Control Platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Eli Lilly's (LLY) Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022
December 14, 2021 5:01 PM ESTEli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at one year in LUCENT-2, a Phase 3 maintenance study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderately-to-severely... More
Foghorn’s (FHTX) Lilly/Loxo Deal is All-Around Positive, Validates Robust Drug Discovery Engine - Analyst
December 13, 2021 9:59 AM ESTEarlier today, Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. The collaboration includes a co-development... More
Foghorn Therapeutics Inc. (FHTX) Climbs 37% Following Pact with Eli Lilly & Co. (LLY)
December 13, 2021 6:15 AM ESTFoghorn Therapeutics Inc. (NASDAQ: FHTX) Climbs 37% Following Pact with Eli Lilly & Co. (NYSE: LLY)
... More